Therefore, exploration of KRAS G12/G13 mutational load in cfDNA has great potential in assisting clinicians not only in predicting patients’ outcomes but also for treatment monitoring, towards the optimal management of NSCLC patients. This evidence concerns the gene KRAS and non-small cell lung carcinoma.